3 Biotech Stocks Projected to Grow Their EPS by at Least 415% in 2018


In many instances, the deck is stacked against biotech companies succeeding. Most discovery-stage, preclinical, and clinical trials fail to meet the mark, meaning most discoveries made in a lab won't make it to pharmacy shelves.



from Biotech News